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Ulcerative colitisInﬂammatory bowel disease (IBD) includes three main disorders: ulcerative colitis, Crohn's disease, and micro-
scopic colitis. The etiology of IBD is unknown and the current treatments are not completely satisfactory. Interac-
tions between the gut neurohormones and the immune system are thought to play a pivot role in inﬂammation,
especially in IBD. These neurohormones are believed to include members of the neuropeptide YY (NPY) family,
which comprises NPY, peptide YY (PYY), and pancreatic polypeptide (PP). Understanding the role of these pep-
tides may shed light on the pathophysiology of IBD and potentially yield an effective treatment tool. Intestinal
NPY, PYY, and PP are abnormal in both patients with IBD and animal models of human IBD. The abnormality in
NPY appears to be primarily caused by an interaction between immune cells and the NPY neurons in the enteric
nervous system; the abnormalities in PYY and PP appear to be secondary to the changes caused by the abnormal-
ities in other gut neurohormonal peptides/amines that occur during inﬂammation. NPY is themember of the NPY
family that can be targeted in order to decrease the inﬂammation present in IBD.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Inﬂammatory bowel disease (IBD) comprises three main disorders:
ulcerative colitis (UC), Crohn's disease (CD), and microscopic colitis
(MC). These disorders exhibit distinct clinical courses, organ speciﬁc-
ities, and histopathological features (El-Salhy et al. 2012a, 2013a).
UC, CD, and MC are chronic diseases; and while UC and CD patientslogy, Department of Medicine,
El-Salhy),
. This is an open access article underexperience infrequent relapses with years of complete remission, fre-
quent relapses, or chronic active disease, MC patients typically experi-
ence chronic active disease (Danese and Fiocchi 2006; El-Salhy et al.
2013a; Nunes et al. 2011). The inﬂammation in CD is transmural in
nature and occurs in any part of the gastrointestinal tract, while the in-
ﬂammation in UC is more superﬁcial and affects the rectocolonic muco-
sa, and the inﬂammation in MC manifests as mucosal and submucosal
inﬁltration of immune cells without ulcerations or crypt abscesses and
occurs in the colon (El-Salhy et al. 2012a, 2013a). In contrast to UC
and CD, spontaneous symptomatic remission in MC has been reported
to occur in 59–93% of the patients (Baert et al. 1999; Mullhaupt et al.
1998). The onset of UC and CD occurs more commonly at a young agethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(i.e., N60 years) (Carter et al. 2004; El-Salhy et al. 2013a). In addition to
the morbidity associated with IBD, it has a marked negative impact on
the quality of life (El-Salhy et al. 2013a; Podolsky 2002a, 2002b).
The etiology of IBD is unknown and the current treatments are not
completely satisfactory (El-Salhy et al. 2012a, 2013a). Treatments with
5-aminosalicylates and corticosteroids are not effective for most
patients over the long term (El-Salhy et al. 2012a), and the short- and
long-term side effects of the thiopurine analogsmercaptopurine, azathi-
oprine, and methotrexate restrict their use (El-Salhy et al. 2012a).
Biological agents such as antibodies against tumor necrosis factor (TNF)
α are effective in only about 65% of UC and CD patients. Surgical treat-
ment can result in malnutrition and eventual short-bowel syndrome in
CD patients, and severe diarrhea in UC patients (El-Salhy et al. 2012a).
The interaction between the neuroendocrine peptides/amines of the
gut and the immune systemhas been the focus of recent research, and it
has been suggested that this interaction plays an important role in the
pathophysiology of IBD (Ameri and Ferone 2012; Bampton and
Dinning 2013; Farzi et al. 2015; Khan and Ghia 2010; Margolis and
Gershon 2009). It is believed that an improved understanding of the
role of the gut neuroendocrine peptides/amines in IBD will lead to the
application of agonists or antagonists to these peptides/amines that rep-
resent a potentially signiﬁcant therapeutic opportunity in IBD. The role
of the neuropeptide Y (NPY) family in IBD has been discussed previous-
ly (El-Salhy et al. 2013b; El-Salhy et al. 2002; Vona-Davis andMcFadden
2007; Wheway et al. 2007a, 2007b; Wheway et al. 2005). The present
review summarizes the available data on the NPY family in IBD and
speculates on its role in the pathophysiology of this disease.
2. The NPY family of peptides
The NPY family comprises three peptides—namely NPY, peptide YY
(PYY), and pancreatic polypeptide (PP) (Adrian et al. 1985; Tatemoto
1982a, 1982b; Tatemoto and Mutt 1980; Tatemoto et al. 1985)—that
act as hormones and/or neurotransmitters/neuromodulators. These
peptides consists of 36 amino acid residues and are structurally related
(Vona-Davis and McFadden 2007). NPY is expressed in multiple neuro-
nal systems of the brain, from the medullary brainstem to the cerebral
cortex, and in enteric neurons including secretomotor and inhibitory
motoneurones (Brumovsky et al. 2007; Eaton et al. 2007; Kask et al.
2002; Tatemoto 1982b; Tatemoto et al. 1985; Vona-Davis and McFad-
den 2007; Wettstein et al. 1995), while PYY and PP are localized in
endocrine cells in the ileum, colon, and rectum (El-Salhy et al. 1983a;
El-Salhy et al. 1982; El-Salhy et al. 1983b). PP is also found in endocrine
cells in the pancreatic islets of Langerhans (Adrian et al. 1985).
All three peptides belonging to the NPY family exert their actions
by binding to at least six Y-receptor subtypes of transmembrane G-
protein-coupled receptors (Vona-Davis and McFadden 2007). Five Y
receptors are expressed in mammals (including humans), namely Y1,
Y2, Y4, Y5, and Y6 (Farzi et al. 2015). NPY and PYY bind to and activate
receptors Y1, Y2, and Y5, and PP binds to receptor Y4 (Cox et al. 2001;
Cox and Tough 2002; Hyland and Cox 2005; Hyland et al. 2003). Recep-
tors Y1, Y2, and Y4 have been found in the colon and small intestine,
localized to epithelial cells and neurons belonging to the submucosal
and myenteric plexus (Cox et al. 2001; Cox and Tough 2002; Gregor
et al. 1996a; Gregor et al. 1996b; Gue et al. 1996; Inui et al. 1992; Mao
et al. 1996; Sheikh and Williams 1990; Walsh et al. 1993; Wharton
et al. 1993; Yan et al. 1996).
The NPY family of peptides exerts multiple physiological effects
upon binding to their receptors. NPY and PYY exert similar biological
effects, which differ from the effects of PP. NPY and PYY delay gastric
emptying and are mediators of the ileal brake; they also inhibit gastric
and pancreatic secretion, and stimulate the absorption of water and
electrolytes (El-Salhy et al. 2014; El-Salhy et al. 2012d; Vona-Davis
andMcFadden 2007). The effects of NPY in the gut aremuch less potent
than those of PYY (Gomez et al. 1995). PP stimulates gastric acidsecretion and the motility of the stomach and small intestine, relaxes
the gallbladder, and inhibits pancreatic secretion (El-Salhy et al. 2014;
El-Salhy et al. 2012d).
All members of the NPY peptide family play a pivotal role in regulat-
ing the appetite and food intake (Konturek et al. 2004; Nguyen et al.
2011). NPY is expressed in two populations of neurons in the arcuate
nucleus (ARC) of the hypothalamus: (1) those expressing both NPY
and AgRP (Agouti-related peptide), and (2) those containing NPY and
POMC (the pro-opiomelanocortin and cocaine and amphetamine-
regulated transcript)—the former neurons stimulate food intake while
the latter suppress it (Ellacott and Cone 2004; Nguyen et al. 2011;
Ollmann et al. 1997). The ARC lies in the median eminence, which
lacks a complete blood–brain barrier and is thus susceptible to factors
circulating in the blood (Cone et al. 2001; Peruzzo et al. 2000; Yu
2012). The ARC is the center for integrating neurological and blood-
borne signals. Similarly, the brainstem is proximal to other regions
with an incomplete blood–brain barrier, thus allowing it to receive
blood-borne signals (Chaudhri et al. 2006; Yu 2012). PYY is released
into the circulation in response to meal ingestion (Adrian et al. 1985).
Infusing PYY3-36 was found to reduce food consumption during test
meals. Moreover, obese subjects were shown to have a low plasma
level of PYY (Batterham et al. 2003; Batterham et al. 2002). Circulating
PYY3-36 binds to the Y2 receptors on the presynaptic terminals of
hypothalamic NPY neurons, inactivating them and resulting in the in-
duction of anorexia (Michel et al. 1998). By regulating the ileal break,
PYY inhibits further food intake once nutrients have reached the distal
small intestine (ileum) (Lin et al. 1996a, 1997; Lin et al. 1996b;
Maljaars et al. 2007; Maljaars et al. 2008a; Maljaars et al. 2008b;
Ohtani et al. 2001; Pironi et al. 1993; Van Citters and Lin 1999, 2006).
Similar to PYY, PP reduces appetite and food intake (Jesudason et al.
2007; Zhang et al. 2012).
3. The NPY family and inﬂammation
The sympathetic neurons that innervate lymphoid organs contain
NPY, which is co-released with norepinephrine upon stimulation
(Lundberg et al. 1989; Romano et al. 1991). NPY is produced by T
lymphocytes, macrophages, monocytes, and dendritic cells during in-
ﬂammation, and it modulates the immune cell activities via a paracrine
or autocrine mode of action (Macia et al. 2012; Schwarz et al. 1994;
Wheway et al. 2005). The Y1 and Y2 receptors are localized on immune
cells including macrophages, neutrophils, granulocytes, and lympho-
cytes, with the Y1 receptor being the most abundant (Bedoui et al.
2008; Chandrasekharan et al. 2013b; Dimitrijevic et al. 2005;
Dimitrijevic and Stanojevic 2013; Dimitrijevic et al. 2010; Singer et al.
2013). The binding of NPY to these receptors inﬂuences the activities
of the immune cells (Farzi et al. 2015; Petitto et al. 1994) in either a
pro- or an anti-inﬂammatory manner (Farzi et al. 2015; Wheway et al.
2005). NPY plays a distinctive role in the immunity of the gastrointesti-
nal tract since NPY nerve ﬁbers are in close contact with immune cells
(Shibata et al. 2008), and there is compelling evidence that NPY exerts
a proinﬂammatory action in the gut (Chandrasekharan et al. 2008;
Chandrasekharan et al. 2013a; Farzi et al. 2015; Hassani et al. 2005;
Holzer et al. 2012; Painsipp et al. 2011; Pang et al. 2010; Wheway
et al. 2005).
PYY mRNA has been found in mouse macrophages (Macia et al.
2012), and PYY increases the adhesion of macrophages, chemotaxis,
phagocytosis, and production of superoxide anions (De la Fuente et al.
1993). The exact role of PP in inﬂammation has not yet been determined.
4. Abnormalities in the NPY family in IBD
The induction of colitis in mice using either dextran sodium sulfate
(DSS) or Salmonella-typhimurium-pretreated streptomycin lead to an
increase in NPY enteric neurons and hyperplasia of NPY nerve ﬁbers
(Bjorck et al. 1997; Chandrasekharan et al. 2008). Surgical resection of
Fig. 1. PYY cells in the colon of a healthy subject (A) and in the colon of a patient with lymphocytic colitis (B).
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rons in the myenteric plexus (Belai et al. 1997). The plasma levels of
NPYwere lower in patients with either CD or UC in remission or relapse
than in controls, although the difference was not statistically signiﬁcant
(Fagerstam et al. 2000). The density of PYY cells is increased in patients
with UC or MC (Fig. 1), in rats with DSS-induced colitis, and in interleu-
kin (IL)-2-gene knock-out mice (Fig. 2) (El-Salhy et al. 1997; El-Salhy
et al. 2012c; El-Salhy et al. 2015; Qian et al. 2000). The strong correlation
between the densities of PYY cells and immune cells found in DSS-
induced colitis in rats supports the presence of an interaction between
these endocrine cells and the immune cells. The PP cell density is
reduced in patientswith UC and CD, and in ratswithDSS-induced colitis
(Fig. 3) (El-Salhy et al. 1997; El-Salhy et al. 2015).
IBD patients experience social and psychological stress, and the
psychological stress negatively inﬂuences intestinal inﬂammation
(Ghia et al. 2009a; Mittermaier et al. 2004). NPY plays a signiﬁcant
role in stress (Farzi et al. 2015), and it is reasonable to expect changes
in brain NPY to be associated with IBD. Hyperreﬂexia of the autonomic
nervous system has been reported in patients with CD and UC, with
this hyperreﬂexia being signiﬁcantly associated with the disease
severity (Straub et al. 1997). Increases in TNF or IL-6 that occur during
the inﬂammation in CD and UC activate the hypothalamus autonomic
nervous system axis, as detected by NPY plasma levels, and the
hypothalamic-pituitary-adrenal axis as measured by the serum cortisol
levels (Straub et al. 2002). That study found a negative correlation
between the serum cortisol and plasma NPY levels in IBD patients.
Alterations of NPY, NPY receptor Y1, and corticotropin-releasing
hormone gene expression were detected in DSS-induced colitis in
mice (Reichmann et al. 2015). Moreover, the combination of DSS-
induced colitis and stress increased the levels of IL-6 and growth-
regulated oncogene-α in the brain (Reichmann et al. 2015). An increase
in circulating NPY and a decrease in the hippocampal expression of NPY
mRNAwere found inmicewithDSS-induced colitis (Hassan et al. 2014).Fig. 2. Colonic PYY cells in a control rat (A) aRepeated stress induced by water-avoidance tests in mice with DSS-
induced colitis elevated the circulating corticosterone level and the
expression of hypothalamic NPY mRNA (Hassan et al. 2014).
5. Role of the NPY family in IBD
During the inﬂammation process, the NPY-family peptides interact
and integrate with other neurohormonal peptides of the gut such as
substance P, vasoactive polypeptide, serotonin, and somatostatin. A
more complete understanding of the role of the NPY-family peptides
in IBD requires consideration of two other neurohormonal peptides:
serotonin and somatostatin. An interaction between NPY and serotonin
in the brain has been reported (Shibata et al. 2008; Shimizu and Bray
1989), and administering NPY into the ventromedial and lateral
hypothalamus of rats decreased the concentration of serotonin and its
metabolite 5-HIAA (Shimizu and Bray 1989). Injecting rats with a sero-
tonin antagonist increased the level of hypothalamic NPY mRNA
(Shibata et al. 2008). Serotonin is believed to play a pivotal role in intes-
tinal inﬂammation (Khan and Ghia 2010; Spiller 2008). IL-13 receptors
have been localized on serotonin cells (Wang et al. 2007), and serotonin
receptors have been found in several immune cells including lympho-
cytes, monocytes, macrophages, and dendritic cells (Cloez-Tayarani
and Changeux 2007). Serotonin also affects the proliferation of lympho-
cytes, protects natural killer cells, inhibits the apoptosis of immune cells,
and promotes the recruitment of T cells (Betten et al. 2001; Laberge
et al., 1996; Soga et al. 2007; Stefulj et al. 2001). The onset of DSS-
induced colitis was delayed and its severity was decreased in mice
deﬁcient in tryptophan hydroxylase 1, and the level of serotonin in
the gastrointestinal tract is reduced in these mice (Ghia et al. 2009b).
Furthermore, restoring serotonin levels in this experimental model
using the serotonin-precursor 5-hydroxytryptophan increased the se-
verity of theDSS-induced colitis (Ghia et al. 2009b). Serotonin is consid-
ered to be proinﬂammatory during the inﬂammatory process. Thend in a rat with DSS-induced colitis (B).
Fig. 4.A. Schematic of the possible role ofmembers of theNPY family in thepathophysiology of IBD. The immune cells interactwithNPYneurons in the enteric nervous systemandwith the
mucosal serotonin and somatostatin cells. This interaction results in increased densities of NPY neurons and serotonin cells, as well as a decreased density of somatostatin cells—these
changes would result in accelerated gastrointestinal motility and increased intestinal secretion (diarrhea). As a feedback response to increased gut motility and secretion, the density of
mucosal PYY cells increases and that of PP cells decreases. B. Schematic of the possible consequences of administering an NPY receptor antagonist in IBD. Blocking the NPY receptors
would decrease the proliferation of immune cells and the production of proinﬂammatory cytokines, which would in turn result in normal densities of NPY neurons and cells containing
serotonin and somatostatin. The absence of changes in the densities of NPY cells, serotonin, and somatostatin would return the gastrointestinal motility and secretion normal, and so
not stimulate any changes in PYY and PP cells.
Fig. 3. PP cells in the colon of a control rat (A) and in the colon of a rat with DSS-induced colitis (B).
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Fig. 4 (continued).
141M. El-Salhy, T. Hausken / Neuropeptides 55 (2016) 137–144density of colonic serotonin has been reported to be high in patients
with UC, CD, and MC, as well as in animal models of colitis (Bertrand
and Bertrand 2010; El-Salhy et al. 1997; El-Salhy et al. 2012b; El-Salhy
et al. 2015; Oshima et al. 1999; Qian et al. 2000). Serotonin stimulates
gastric and intestinalmotility, modulates visceral sensitivity, and stimu-
lates intestinal secretion (El-Salhy et al. 2012c; El-Salhy et al. 2012d).
The increase in serotonin in IBD may lead to increase gastric and intes-
tinal motility as well as increased intestinal secretion.
Somatostatin exerts its actions by binding to ﬁve membrane
G-protein-coupled receptors subtypes, which are designated as
somatostatin receptors 1–5 (Ferone et al. 2005). Somatostatin recep-
tors have been localized on different immune cells such asmonocytes/
macrophages, B lymphocytes, T lymphocytes, and dendritic cells
(Armani et al. 2007; Dalm et al. 2003; Ferone et al. 2012; Ferone et al.
2002; Ferone et al. 2005; Hagstromer et al. 2006; Lichtenauer-Kaligis
et al. 2004; Talme et al. 2001; Taniyama et al. 2005; ten Bokum et al.
2000). Somatostatin stimulates the proliferation of B lymphoblasts by
enhancing the formation of immunoglobulins (Rosskopf et al. 2003),and inhibits T-lymphocyte proliferation and reduces theproinﬂammato-
ry cytokines such as interferon-γ (Casnici et al. 1997; Radosevic-Stasic
et al. 1995; Sirianni et al. 1994; ten Bokum et al. 2000). Somatostatin is
considered to also exert anti-inﬂammatory effects (Ameri and Ferone
2012; Helyes et al. 2007; Helyes et al. 2009). The somatostatin cell den-
sity is decreased in the colon of patientswithUC and CD, aswell as in an-
imal models of induced colitis (El-Salhy et al. 2015; Koch et al. 1988;
Watanabe et al. 1992). Somatostatin inhibits intestinal motility, as well
as gastrointestinal exocrine and neuroendocrine secretion (El-Salhy
et al. 2012d). The decrease in somatostatin would result in the further
acceleration of gastrointestinal motility and an increase in intestinal
secretion.
Based on the data presented in this review, it can be speculated that
the immune cells interact with NPY neurons, serotonin cells, and
somatostatin cells during inﬂammation (Fig. 4A). This interaction re-
sults in increased densities of NPY neurons in the enteric nervous sys-
tem and of serotonin cells in the mucosa, and a decrease in mucosal
somatostatin cells. As mentioned above, both NPY and serotonin have
142 M. El-Salhy, T. Hausken / Neuropeptides 55 (2016) 137–144proinﬂammatory actions, and somatostatin is an anti-inﬂammatory
peptide. The changes in these neurohormonal peptides/amines would
cause accelerated gastrointestinal motility and increased intestinal
secretion, resulting in diarrhea, which is the cardinal symptom in IBD.
As a feedback response to the accelerated gastrointestinal motility and
increased intestinal secretion, the cell density of PYY increases while
that of PP decreases. These observations indicate that NPY should be a
treatment target for the inﬂammation that occurs in IBD, which is also
supported by the results obtained in DSS-induced colitis in rodents
(Hassani et al. 2005; Pang et al. 2010). Administering NPY antisense
oligodeoxynucleotides to rats with DSS-induced colitis improves the
inﬂammation and decreases the levels of NPY and TNFα and the expres-
sions of p-Akt and p-NFκB (Pang et al. 2010). The DSS-induced colitis
was clinically attenuated in mice with a genetically deﬁcient NPY Y1
receptor and in those administered with intraperitoneal Y1 receptor
antagonist (Hassani et al. 2005). These data suggest that a Y1 receptor
antagonist should be used to treat IBD. However, since the Y1 receptor
is involved in many biological processes and its administration may in-
terfere with other important biological functions (Balasubramaniam
1997; Hassani et al. 2005; Pang et al. 2010), it might be preferable to
consider using a Y2 receptor antagonist instead.
6. Conclusion
The levels of all members of the NPY peptide family are abnormal
in both patients with IBD and animal models of human IBD. These neu-
rohormones appear to play a role in the pathophysiology of IBD by
interacting and integrating with other gut neurohormonal peptides/
amines. The primary changes seen in IBD appear to be related to NPY
and are attributable to an interaction with immune cells during the
inﬂammatory process. On the other hand, changes in PYY and PP appear
to be secondary to changes in other gut neurohormonal peptides such
as NPY, serotonin, and somatostatin. Therefore, NPY appears to be a
key member of the NPY family during the inﬂammatory process in
IBD, indicating the potential of NPY antagonists in therapies for amelio-
rating the inﬂammation in IBD.
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